Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

If You Invested $100 In This Stock 5 Years Ago, You Would Have $400 Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 21.93% on an annualized basis producing an average annual return of 31.32%. Currently, Eli Lilly has a market capitalization of $307.03 billion.

Benzinga

The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Executives Sell More Than $67M Of 5 Stocks: NetApp, Eli Lilly And More

US gold futures traded lower on Friday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

This Is What Whales Are Betting On Eli Lilly

A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 17 strange trades.

Benzinga

LLY's New Drug Lineup Looks Promising For Investors

Eli Lilly and Company’s (LLY) new drug line-up is expected to generate higher revenues and earnings. Also, LLY’s robust earnings, favorable analyst estimates, and higher-than-industry profitability make it a promising investment option. Read on….

StockNews.com

About 4,000 women with breast cancer could benefit from new twice-daily pill

The drug, made by Eli Lilly, is suitable for those with hormone receptor-positive, HER2-negative, node-positive early breast cancer.

The Independent UK

Peering Into Eli Lilly's Recent Short Interest

Eli Lilly's (NYSE:LLY) short percent of float has risen 4.76% since its last report. The company recently reported that it has 5.23 million shares sold short, which is 0.66% of all regular shares that are available for trading.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,000 Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 15 years by 5.21% on an annualized basis producing an average annual return of 11.42%. Currently, Eli Lilly has a market capitalization of $273.33 billion.

Benzinga

Looking At Eli Lilly's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 35 strange trades.

Benzinga

Looking At Eli Lilly's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Executives Sell Over $100M Of 4 Stocks

Gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

Executives Sell Around $207M Of 5 Stocks

Gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

What 7 Analyst Ratings Have To Say About Eli Lilly

Eli Lilly (NYSE:LLY) has observed the following analyst ratings within the last quarter:

Benzinga

Why Eli Lilly Shares Are Rising Today

Eli Lilly And Co (NYSE: LLY) shares are trading higher by 3.58% at $296.48 after the company announced the CHMP has issued a positive opinion for OLUMIANT for the treatment of adults with severe alopecia areata.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial

The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's (NASDAQ:FHTX) Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The FDA initiated the partial clinical hold following the report of a recent death that occurred in a subject with potential differentiation syndrome. Differentiation…

Benzinga

PepsiCo And 3 Other Stocks Insiders Are Selling

US crude oil futures traded lower, dropping around 1% on Thursday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

How Is The Market Feeling About Eli Lilly?

Eli Lilly's (NYSE:LLY) short percent of float has risen 6.85% since its last report. The company recently reported that it has 6.22 million shares sold short, which is 0.78% of all regular shares that are available for trading.

Benzinga

Check Out What Whales Are Doing With LLY

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 11 strange trades.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas

Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The company’s loss tripled last year on growing competition for its core product, whose sales fell 22% in this year’s first-quarter

Benzinga

FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19

The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients.

Benzinga

Eli Lilly's Olumiant Becomes First FDA Approved Immunomodulatory Treatment For COVID-19

The FDA approved Eli Lilly And Co's (NYSE:LLY) Olumiant (baricitinib) for COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Olumiant is the first immunomodulatory treatment for COVID-19 to receive FDA approval. The FDA first issued an emergency use authorization (EUA) for Olumiant combined with remdesivir to treat…

Daily Mirror

Weight loss: Weekly jab tricks body into feeling full and causes 24kg drop

Participants in the trial lost an average of 22.5 per cent of their body weight. This is more than twice the normal effectiveness of such treatments and could be an alternative to surgery for people living with obesity.

The Independent UK

Mower, co-inventor of implantable defibrillator, dies at 89

A cardiologist who helped invent an automatic implantable defibrillator that has helped countless heart patients live longer and healthier has died

Benzinga

Analyst Ratings for Eli Lilly

Eli Lilly (NYSE:LLY) has observed the following analyst ratings within the last quarter:

Benzinga

Here's How Much $1000 Invested In Eli Lilly 10 Years Ago Would Be Worth Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 9.8% on an annualized basis producing an average annual return of 21.54%. Currently, Eli Lilly has a market capitalization of $276.68 billion.

1 … 27 28 29 30

People

Dipanjan BanchurSince

722 stories

Helen Knight

25 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.